Sam Brusco, Associate Editor04.01.22
BD (Becton, Dickinson and Company) has completed its spinoff of embecta, its former diabetes care business. embecta is now considered one of the largest pure-play diabetes management firms in the world.
"The completion of this spinoff is a significant achievement for both BD and embecta," Tom Polen, chairman, CEO, and president of BD told the press. "While BD is proud of its heritage in the diabetes care category, we are just as excited to see our legacy advanced by embecta as a newly independent, publicly-traded corporation. Moving forward, each of our organizations will be able to focus on investment and innovation in our respective core businesses, support our customers and the patients they serve, drive strategic growth and enhance long-term shareholder value."
BD’s strategy is to create two independent companies with attractive long-term value for BD shareholders. embecta aims to build on its foundation as a leading maker of diabetes injection tech. BD retains no ownership in embecta.
"The completion of this spinoff is a significant achievement for both BD and embecta," Tom Polen, chairman, CEO, and president of BD told the press. "While BD is proud of its heritage in the diabetes care category, we are just as excited to see our legacy advanced by embecta as a newly independent, publicly-traded corporation. Moving forward, each of our organizations will be able to focus on investment and innovation in our respective core businesses, support our customers and the patients they serve, drive strategic growth and enhance long-term shareholder value."
BD’s strategy is to create two independent companies with attractive long-term value for BD shareholders. embecta aims to build on its foundation as a leading maker of diabetes injection tech. BD retains no ownership in embecta.